Technology
Health
Biotechnology
Actinium Pharmaceuticals
$0.559876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$0.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.009 (-1.61%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ATNM and other stocks, options, ETFs, and crypto commission-free!
About
Actinium Pharmaceuticals, Inc, also called Actinium Pharmaceuticals, is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Read More Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
CEO
Employees
30
Headquarters
New York, New York
Founded
1993
Market Cap
64.68M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.12M
High Today
$0.5737
Low Today
$0.54
Open Price
$0.5577
Volume
706.91K
52 Week High
$0.8651
52 Week Low
$0.3323
Collections
Technology
Health
Biotechnology
2013 IPO
US
North America
News
Yahoo FinanceMar 7
What Type Of Shareholder Owns Actinium Pharmaceuticals, Inc.’s (NYSEMKT:ATNM)?
A look at the shareholders of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. Companies that used to be publicly owned tend to have lower insider ownership. With a market capitalization of US$68m, Actinium Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownersh...
MarketBeatMar 6
Stock Price, News, & Analysis for Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatm...
Price Paid on Robinhood
23% Lower
Right Now
52 Week Low
$0.3323
Average Price Paid
$0.7176
52 Week High
$0.8651
Earnings
-$0.14
-$0.11
-$0.07
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.06 per share
Actual
-$0.05 per share